Disseminated intravascular coagulation associated with hematologic malignancies

Hematological malignancies that are frequently complicated with disseminated intravascular coagulation (DIC) include acute leukemia, high-grade malignant lymphoma, and cases undergoing certain immunotherapy or cellular therapy. In typical cases of DIC associated with hematological malignancies, blee...

Full description

Saved in:
Bibliographic Details
Published in:Rinshō ketsueki Vol. 66; no. 8; p. 822
Main Author: Fukatsu, Masahiko
Format: Journal Article
Language:Japanese
Published: Japan 2025
Subjects:
Disseminated Intravascular Coagulation - diagnosis
Disseminated Intravascular Coagulation - etiology
Disseminated Intravascular Coagulation - therapy
Hematologic Neoplasms - complications
Hematologic Neoplasms - therapy
Humans
Tranexamic acid
Thrombomodulin
Antithrombin
Serine protease inhibitor
ISSN:0485-1439
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hematological malignancies that are frequently complicated with disseminated intravascular coagulation (DIC) include acute leukemia, high-grade malignant lymphoma, and cases undergoing certain immunotherapy or cellular therapy. In typical cases of DIC associated with hematological malignancies, bleeding symptoms are aggravated not only by the activated fibrinolytic system but also by thrombocytopenia induced by the underlying disease or anticancer therapy, and their management is of critical clinical interest. As such, antithrombotic therapy with heparinoids carries significant risk of bleeding complications. Other DIC treatments, such as thrombomodulin and antithrombin, are preferred, although none of them lack the high-quality evidence necessary to be strongly recommended. It is essential to diagnose DIC early using appropriate diagnostic criteria, comprehend the pathophysiology of each case, and select treatments based on an understanding of the benefits and potential risks of the individual therapeutic agents. The inclusion of replacement therapy with blood transfusions and blood products, the optimal intervention threshold for hematological malignancy-associated DIC, and strategies for identifying optimal cases that would most benefit from specific treatment, remain subjects for future investigation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0485-1439
DOI:10.11406/rinketsu.66.822